Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd (the "Company") was submitted on October 16, 2025. The report discloses a significant change in beneficial ownership by an executive officer rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of share acquisition activity.
Material Changes
- Executive Share Acquisition: Panetta Partners Limited, an entity in which Gabriele Cerrone (Executive Chairman) has a beneficial interest, acquired 210,000 ordinary shares of the Company on NASDAQ.
- Total Holdings: Following this transaction, Mr. Cerrone's total beneficial holding stands at 10,382,677 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to furnish the news announcement regarding the share purchase as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact percentage of total outstanding shares represented by the new holding of 10,382,677 shares.
- Confirm the purchase price per share for the 210,000 shares acquired by Panetta Partners Limited.
- Review the full text of Exhibit 99.1 for any additional context regarding the Executive Chairman's intent or future trading plans.